(BBWI) Bath & Body Works - Ratings and Ratios
Exchange: NYSE • Country: United States • Currency: USD • Type: Common Stock • ISIN: US0708301041
BBWI: Soaps, Candles, Lotions, Fragrances, Sanitizers
Bath & Body Works Inc. (NYSE:BBWI) is a leading specialty retailer primarily focused on home fragrance, body care, and personal hygiene products. The company operates under well-known brands such as Bath & Body Works and White Barn, leveraging a diverse distribution network that includes retail stores across the U.S. and Canada, as well as international partnerships through franchise, license, and wholesale arrangements. This strategic approach allows BBWI to maintain a strong market presence while exploring global growth opportunities.
BBWIs product portfolio encompasses a wide range of items, including candles, soaps, sanitizers, and body care products. The company has successfully expanded its reach through e-commerce, which has been a key driver of recent growth. With a significant number of stores and a robust online platform, BBWI continues to adapt to evolving consumer preferences, ensuring relevance in a competitive retail landscape.
From a financial standpoint, BBWI boasts a market capitalization of approximately $7.68 billion, with a trailing P/E ratio of 8.80 and a forward P/E of 9.58, indicating moderate valuation levels. The price-to-sales ratio of 1.04 reflects a reasonable valuation relative to its revenue. However, the absence of a P/B ratio may signal potential concerns regarding the companys book value, which could be a point of scrutiny for investors.
Investors should consider the risks associated with BBWI, including intense competition in the retail sector, potential disruptions in global supply chains, and the challenges of maintaining growth in a saturated market. Despite these risks, BBWIs strong brand recognition and strategic initiatives position it as a contender in the specialty retail industry, warranting careful consideration for those assessing investment opportunities in this space.
Additional Sources for BBWI Stock
Tweets: X Stocktwits
Fund Manager Positions: Dataroma Stockcircle
BBWI Stock Overview
Market Cap in USD | 7,899m |
Sector | Consumer Cyclical |
Industry | Specialty Retail |
GiC Sub-Industry | Other Specialty Retail |
IPO / Inception | 1985-07-01 |
BBWI Stock Ratings
Growth 5y | 29.6% |
Fundamental | 9.92% |
Dividend | 61.3% |
Rel. Strength Industry | -33 |
Analysts | 3.85/5 |
Fair Price Momentum | 35.09 USD |
Fair Price DCF | 30.35 USD |
BBWI Dividends
Dividend Yield 12m | 2.00% |
Yield on Cost 5y | 4.41% |
Annual Growth 5y | 26.91% |
Payout Consistency | 86.0% |
BBWI Growth Ratios
Growth Correlation 3m | 22.1% |
Growth Correlation 12m | -60.8% |
Growth Correlation 5y | 15.9% |
CAGR 5y | 17.13% |
CAGR/Mean DD 5y | 0.50 |
Sharpe Ratio 12m | -0.12 |
Alpha | -31.23 |
Beta | 0.86 |
Volatility | 37.42% |
Current Volume | 8147.9k |
Average Volume 20d | 3038.3k |
As of February 19, 2025, the stock is trading at USD 40.00 with a total of 8,147,896 shares traded.
Over the past week, the price has changed by +12.83%, over one month by +7.27%, over three months by +28.02% and over the past year by -13.74%.
Neither. Based on ValueRay Fundamental Analyses, Bath & Body Works is currently (February 2025) neither a good nor a bad stock to buy. It has a ValueRay Fundamental Rating of 9.92 and therefor a neutral outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of BBWI as of February 2025 is 35.09. This means that BBWI is currently overvalued and has a potential downside of -12.28%.
Bath & Body Works has received a consensus analysts rating of 3.85. Therefor, it is recommend to buy BBWI.
- Strong Buy: 7
- Buy: 4
- Hold: 8
- Sell: 1
- Strong Sell: 0
According to ValueRays Forecast Model, BBWI Bath & Body Works will be worth about 41 in February 2026. The stock is currently trading at 40.00. This means that the stock has a potential upside of +2.5%.
Issuer | Forecast | Upside |
---|---|---|
Wallstreet Target Price | 45.9 | 14.7% |
Analysts Target Price | 45.3 | 13.4% |
ValueRay Target Price | 41 | 2.5% |